27 Multiple Myeloma Clinical Trials in Phoenix, AZ (2026)

Q: How do I join a clinical trial in Phoenix?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you.

Recruiting Multiple Myeloma Studies in Phoenix

NCT05243797Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclista...

Phoenix, AZPHASE31,594 participantsStichting European Myeloma Network

View Study Details

NCT04566328Recruiting

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethason...

Phoenix, AZPHASE31,450 participantsECOG-ACRIN Cancer Research Group

View Study Details

NCT07764978Recruiting

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard ...

Phoenix, AZPHASE3750 participantsAstraZeneca

View Study Details

NCT07518186Recruiting

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab....

Phoenix, AZPHASE3700 participantsJanssen Research & Development, LLC

View Study Details

NCT06679101Recruiting

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with T...

Phoenix, AZPHASE3520 participantsGlaxoSmithKline

View Study Details

NCT05561387Recruiting

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receivin...

Phoenix, AZPHASE3510 participantsSWOG Cancer Research Network

View Study Details

NCT07391657Recruiting

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethaso...

Phoenix, AZPHASE3508 participantsAstraZeneca

View Study Details

NCT07258511Recruiting

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody....

Phoenix, AZPHASE3400 participantsJanssen Research & Development, LLC

View Study Details

NCT06931821Recruiting

Functional ElectroAnatomiC Isochronal Late Activation Mapping for Empiric VT Ablation Trial

This is a multicenter, prospective, parallel, randomized controlled trial to test for non-inferiority with an ILAM-guided VT ablation compared to conventional voltage- based ablation. The study has tw...

Phoenix, AZNA360 participantsUniversity of Arizona

View Study Details

NCT05895786Recruiting

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

The purpose of the study is to understand how the study medicine PF-06823859 works in people with idiopathic inflammatory myopathies (DM and PM). These disorders cause inflammation that weakens the mu...

Phoenix, AZPHASE3318 participantsPfizer

View Study Details

NCT05201781Recruiting

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-te...

Phoenix, AZPHASE4295 participantsJanssen Research & Development, LLC

View Study Details

NCT03937635Recruiting

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenal...

Phoenix, AZPHASE3288 participantsECOG-ACRIN Cancer Research Group

View Study Details

NCT06858579Recruiting

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

The purpose of this Phase 3 study is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP)....

Phoenix, AZPHASE3256 participantsDianthus Therapeutics

View Study Details

NCT06455449Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

The purpose of this multicenter, randomized, placebo-controlled and double-blind study is to evaluate the efficacy and safety of subcutaneous anifrolumab compared with placebo on the overall disease a...

Phoenix, AZPHASE3240 participantsAstraZeneca

View Study Details

NCT05850234Recruiting

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma....

Phoenix, AZPHASE1232 participantsAstraZeneca

View Study Details

NCT05650632Recruiting

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain,...

Phoenix, AZPHASE1210 participantsAbbVie

View Study Details

NCT06121843Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants w...

Phoenix, AZPHASE1187 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT06375044Recruiting

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple ...

Phoenix, AZPHASE1130 participantsJiangsu Simcere Pharmaceutical Co., Ltd.

View Study Details

NCT07284758Recruiting

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamet...

Phoenix, AZPHASE2100 participantsC4 Therapeutics, Inc.

View Study Details

NCT07096778Recruiting

Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come b...

Phoenix, AZPHASE2100 participantsCellCentric Ltd.

View Study Details

NCT07086976Recruiting

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

This is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb response (DHR) compared with placebo in approx...

Phoenix, AZPHASE390 participantsSanofi

View Study Details

NCT06630806Recruiting

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

This is a first-in-human study of SAR446523 conducted in patients with RRMM. The study consists of two parts: Dose escalation (Part A): In this part, up to several dose levels (DLs) of SAR446523 wil...

Phoenix, AZPHASE187 participantsSanofi

View Study Details

NCT06544499Recruiting

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, el...

Phoenix, AZPHASE369 participantsargenx

View Study Details

NCT06356571Recruiting

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dex...

Phoenix, AZPHASE264 participantsSanofi

View Study Details

NCT02055105Recruiting

Modulation of Molecular Fingerprinting in Pediatric Sepsis

The goal of this study is to demonstrate the sensitivity and specificity of detecting circulating micro RNA (miRNA) biomarkers in pediatric septic patients. It will also follow expression and modulati...

Phoenix, AZ50 participantsPhoenix Children's Hospital

View Study Details

NCT07073547Recruiting

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM)....

Phoenix, AZPHASE140 participantsAstraZeneca

View Study Details

NCT06465316Recruiting

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating multiple myeloma that has come back after a period of improvement (relapsed)...

Phoenix, AZPHASE126 participantsNational Cancer Institute (NCI)

View Study Details

About Multiple Myeloma Clinical Trials in Phoenix

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 27 multiple myeloma clinical trials recruiting participants in Phoenix, AZ. These studies are seeking a combined 9,574 participants. Research is being sponsored by Stichting European Myeloma Network, ECOG-ACRIN Cancer Research Group, AstraZeneca and 15 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Phoenix — FAQ

Are there multiple myeloma clinical trials in Phoenix?

Yes, there are 27 multiple myeloma clinical trials currently recruiting in Phoenix, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Phoenix?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you about next steps.

Are clinical trials in Phoenix free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Phoenix studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 27 active trials in Phoenix are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated September 7, 2026 from ClinicalTrials.gov